NCT04865887

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Georgetown University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

Detailed description

The primary endpoint of this phase II study is to determine the objective response rate (partial response \[PR\] + complete response \[CR\]) of specific pembrolizumab-lenvatinib combination therapy in patients with locally advanced or metastatic cervical cancer. The phase II portion of the trial will follow Simon's minimax two-stage design1. In the Stage 1, 11 patients will be accrued. If 1 or fewer patients among these 11 patients achieve an objective response with the pembrolizumab-lenvatinib combination therapy, the combination therapy will be rejected and the trial stopped. However, if there are 2 or more patients who exhibit response in the Stage 1, then an additional 24 patients will be entered into the Stage 2, for a total of 35 patients in this phase II study. If 9 or more patients exhibit response among these 35 patients, then the treatment will be considered for further investigation. Any unplanned interim analysis will utilize the sequential conditional probability ratio test (SCPRT)2, which allows an early assessment of statistical evidence for both efficacy and futility, and provides a discordance probability that early trend could be reversed should the trial continue to enroll all 35 patients.

Conditions

• Cervical Cancer
• Metastatic Cervical Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	200mg, every 3 weeks, IV infusion
DRUG	Lenvatinib	20 mg (2 capsules x10mg), daily, orally

Timeline

• Start date: 2022-10-07
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2021-04-29
• Last updated: 2025-10-07

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study